FlavoLife develops senolytic drugs and medical foods to selectively clear stress-induced senescent cells, targeting premature ageing conditions.
FlavoLife is a single company with two pathways for healthy aging and to fight senescence:
1) Senolytic drug candidates developed as 'pan-senolytics,' designed to target a broad and diverse range of senescent cells accumulating throughout the body due to premature ageing
2) Senolytic medical foods, to support reducing chemotherapy toxicity
Key partners
CDP Venture Capital & Cariplo Factory
Key Awards
*VitaFoods 2024: Most Innovative product – Winner
*StartCup Puglia 2022 – Winner
*Premio Nazionale dell’Innovazione 2022 - Finalist
Company Details
- Employees
- 3
- Founded
- 2022
- Address
- Bari, Puglia 70121, It
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.flavolife.com/
- HQ
- Bari, Puglia
Flavolife Questions
Flavolife's website is https://www.flavolife.com/
Flavolife's LinkedIn profile is https://it.linkedin.com/company/flavolife
Flavolife has
3 employees.
View email and phone details for 3
employees at Flavolife.
Flavolife's industry is
Biotechnology Research
Flavolife's top competitors are
Reso Health,
Bionexa,
O.l.v. Pharma,
Ammi (Briofood),
Nurix Therapeutics,
Circular Fiber Srl,
Kitozyme,
Biokuris,
Vera Salus Ricerca,
Hlx Life Sciences.
Flavolife's categories are Biotechnology Research
Flavolife's founding year is 2022
